The latest cancer drugs news
Browsing: Cancer Drug News
ASCO 2020: Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumours
The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed…
FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer
The Food and Drug Administration (FDA) granted accelerated approval to rucaparib for patients with deleterious…
FDA approves ripretinib for advanced gastrointestinal stromal tumour
The Food and Drug Administration (FDA) approved ripretinib, for adult patients with advanced gastrointestinal stromal…
Nanobowls serve up chemotherapy drugs to cancer cells
For decades, scientists have explored the use of liposomes – hollow spheres made of lipid…
FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer
On May 19, 2020, the Food and Drug Administration approved olaparib for adult patients with…
A ‘switch’ that turns autoimmunity drugs into powerful anti-cancer treatments
Scientists from the Antibody and Vaccine group at the University of Southampton, UK, have discovered…
Cell-culture based test systems for anticancer drug screening
As we know, a malignant tumour is a complex system of mutated cells which constantly…
Approval of olaparib offers men first gene-targeted medicine for prostate cancer
The Institute of Cancer Research, London, UK, has strongly welcomed the approval by the US…
ASCO 2020: Trial confirms durable and long-term survival benefit for nivolumab plus ipilimumab over chemotherapy in metastatic first-line non-small cell lung cancer patients
Today three-year follow-up results from Part 1 of the Phase 3 CheckMate -227 trial have…
ASCO 2020: Maintenance therapy With PARP inhibitor olaparib extends survival by over 1 year in patients with relapsed ovarian cancer and BRCA mutation
Maintenance therapy with olaparib extended overall survival by nearly 13 months (12.9) compared with placebo…